Skip to main content

Advertisement

SpringerLink
Log in

Prognostic significance of ADAM17 expression in patients with gastric cancer who underwent curative gastrectomy

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Backgrounds

A disintegrin and metalloproteinase (ADAM) 17 has been indicated to be an indispensable regulator of cellular events from proliferation to migration. Although prognostic importance of ADAM17 expression has been investigated in several tumours, its clinical utility as a useful prognostic molecular marker remains unclear in gastric cancer. In the current study, we evaluated the expression of ADAM17 and its prognostic significance in gastric cancer patients after curative gastrectomy.

Methods

The prognostic significance of ADAM17 expression was analysed immunohistochemically in 156 patients with gastric cancer who had undergone curative gastrectomy, and the relationship between its expression and clinicopathological factors was also evaluated.

Results

High ADAM17 expression was detected in 79 patients (51 %), whereas low expression was found in 77 cases (49 %). There was significant correlation between gender, histology, lymph node metastasis, vascular invasion, the presence of recurrence and high ADAM17 expression. Recurrence in patients with high ADAM17 expression was significantly higher than that for patients with low ADAM17 expression (p = 0.032). The median disease-free survival (DFS) time for patients with tumours with high ADAM17 expression was worse than that of patients with tumours with low ADAM17 expression (16.6 vs. 44.2 months, p = 0.004). In addition, patients with low ADAM17 expression had a higher median overall survival (OS) (49.6 vs. 26.9 months, p = 0.019) compared to those with high ADAM17 expression. Multivariate analysis indicated that the rate of ADAM17 expression was an independent prognostic factor for DFS, in addition to the already known important clinicopathological prognostic indicator. But the prognostic importance of ADAM17 expression could not be proved by multivariate analysis for OS.

Conclusions

The potential value of ADAM17 expression as a useful molecular marker in gastric cancer progression should be evaluated comprehensively; it may predict recurrence and poor prognosis in patients with gastric cancer after curative resection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.

    Article  PubMed  Google Scholar 

  2. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50.

    Article  PubMed  Google Scholar 

  3. Blobel CP. ADAMs: key components in EGFR signaling and development. Nat Rev Mol Cell Biol. 2005;6:32–43.

    Article  CAS  PubMed  Google Scholar 

  4. Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. Mol Asp Med. 2008;29:258–89.

    Article  CAS  Google Scholar 

  5. Gooz M. ADAM-17: the enzyme that does it all. Crit Rev Biochem Mol Biol. 2010;45(2):146–69.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Duffy MJ, McKiernan E, O’Donovan N, McGowan PM. Role of ADAMs in cancer formation and progression. Clin Cancer Res. 2009;15:1140–4.

    Article  CAS  PubMed  Google Scholar 

  7. Rose-John S. ADAM17, shedding, TACE as therapeutic targets. Pharmacol Res. 2013;71:19–22.

    Article  CAS  PubMed  Google Scholar 

  8. Shou ZX, Jin X, Zhau ZS. Upregulated expression of ADAM17 is a prognostic marker for patients with gastric cancer. Ann Surg. 2012;256(6):1014–22.

    Article  PubMed  Google Scholar 

  9. Zhang TC, Zhu WG, Huang MD, Fan RH, Chen XF. Prognostic value of ADAM17 in human gastric cancer. Med Oncol. 2012;29(4):2684–90.

    Article  CAS  PubMed  Google Scholar 

  10. Edge SB, Byrd DR, Compton CC, et al., editors. American Joint Committee on Cancer Staging Manual. 7th ed. Springer, New York; 2010. p. 117.

  11. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma. 2nd English ed. Gastric Cancer. 1998;1:10–24.

    Article  PubMed  Google Scholar 

  12. Katakowski M, Jiang F, Zheng X, Gutierrez JA, Szalad A, Chopp M. Tumorigenicity of cortical astrocyte cell line induced by the protease ADAM17. Cancer Sci. 2009;100:1597–604.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Arribas J, Bech-Serra JJ, Santiago-Josefat B. ADAMs, cell migration and cancer. Cancer Metastasis Rev. 2006;25:57–68.

    Article  PubMed  Google Scholar 

  14. Zheng X, Jiang F, Katakowski M, Zhang ZG, Lu QE, Chopp M. ADAM17 Promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation. Cancer Biol Therapy. 2009;8(11):1045–54.

    Article  CAS  Google Scholar 

  15. Borrell-Pages M, Rojo F, Albanell J, Baselga J, Arribas J. TACE is required for activation of the EGFR by TGF-alpha in tumors. EMBO J. 2003;22:1114–24.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. McGowan PM, Ryan BM, Hill AD, McDermott E, O’Higgins N, Duffy MJ. ADAM-17 expression in breast cancer correlates with variables of tumor progression. Clin Cancer Res. 2007;13:2335–43.

    Article  CAS  PubMed  Google Scholar 

  17. McGowan PM, McKiernan E, Bolster F, Ryan BM, Hill AD, McDermott EW, et al. ADAM-17 predicts adverse outcome in patients with breast cancer. Ann Oncol. 2008;19:1075–81.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

This manuscript was not supported by any financial or other relationships.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Dr. Lutfi Kırdar Kartal Education and Research Hospital, Istanbul, Turkey

    D. Aydin, O. Ercelep, A. Mert, S. Yuksel, M. Ozcelik, D. Isik, H. Surmeli, H. Odabasi & M. Aliustaoglu

  2. Department of Medical Oncology, Medical Faculty, Istanbul Medipol University, Istanbul, Turkey

    A. Bilici

  3. Department of Pathology, Dr. Lutfi Kirdar Education and Research Hospital, Istanbul, Turkey

    D. Yavuzer & A. Tan

  4. Department of Medical Oncology, Kocaeli University School of Medicine, Kocaeli, Turkey

    U. Kefeli

Authors
  1. D. Aydin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Bilici
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Yavuzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. U. Kefeli
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. O. Ercelep
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Mert
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S. Yuksel
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M. Ozcelik
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. D. Isik
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. H. Surmeli
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. H. Odabasi
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. M. Aliustaoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Aydin.

Additional information

This study was presented in ASCO, 2015, Gastrointestinal Cancer Symposium, in a poster session. January 15–17, 2015, San Francisco, California.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aydin, D., Bilici, A., Yavuzer, D. et al. Prognostic significance of ADAM17 expression in patients with gastric cancer who underwent curative gastrectomy. Clin Transl Oncol 17, 604–611 (2015). https://doi.org/10.1007/s12094-015-1283-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-015-1283-1

Keywords

Search

Navigation